Senseonics
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Senseonics sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Senseonics: 7 sponsored US clinical trials, 2 recruiting.
Senseonics sponsors 7 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 4 completed. The most-studied condition in this pipeline is Diabetes Mellitus, Type 2, with 2 trials.
Upper-quartile sponsor footprint
Senseonics sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
ROME GS System Study
NCT07518004
Gemini Study: A Prospective, Multicenter Evaluation of Performance and Safety of the Eversense Gemini System With Flash Glucose Measurement Feature
NCT07386340
Eversense® Non-adjunctive Use Post Approval Study
NCT04836546
Post Approval Study of the Eversense® Continuous Glucose Monitoring
NCT03908125
PROMISE Study: An Evaluation of an Implantable Continuous Glucose Sensor up to 180 Days
NCT03808376
PRECISION Study: Multi-center Study of Performance of a Novel Implanted CGM System Using a Next Generation Transmitter and Algorithm
NCT03251079
Evaluation of the Accuracy of an Implanted Glucose Sensor
NCT02647905
Therapeutic Areas
What is open in the Senseonics pipeline
2 recruiting of 7 indexed (29% open); 4 completed (57%).
Phase labels are sparse on this sponsor index, so phase mix is not charted here.
Top condition: Diabetes Mellitus, Type 2 (2 trials), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Senseonics: open-pipeline peers nationwide
Peers matched on 7 registered trials and 29% open enrollment, not the therapeutic-area sidebar.
Senseonics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 29% open enrollment (± trial volume)
- Alabama Physical Therapy & Acupuncture · 29% recruiting · 14 trials
- AlloSource · 29% recruiting · 7 trials
- Alnylam Pharmaceuticals · 29% recruiting · 49 trials
- Annovis Bio · 29% recruiting · 7 trials
Related
What to do with this Senseonics page
7 registered trials is a research-attention snapshot, not an endorsement of Senseonics or any single study.
- 2 of Senseonics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Diabetes Mellitus, Type 2 is the condition Senseonics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Diabetes Mellitus, Type 2 trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Senseonics pipeline card: 7 registered trials from official public datasets.Report a data error.